Actualités Biocept Inc - BIOC | Actions NASDAQ

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Notice of Effectiveness (effect)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:May 24, 2023 5:30...

Biocept Announces Pricing of $5.0 Million Underwritten Public Offering

Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces the...

Securities Registration Statement (s-1/a)

Table of Contents As filed with the Securities and Exchange Commission on May 23, 2023...

Biocept Announces One-for-Thirty Reverse Stock Split

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that as a result of its...

Securities Registration Statement (s-1/a)

Table of Contents As filed with the Securities and Exchange Commission on May 16, 2023...

Securities Registration Statement (s-1/a)

Table of Contents As filed with the Securities and Exchange Commission on May 15, 2023...

Current Report Filing (8-k)

BIOCEPT INC false 0001044378 0001044378 2023-05-10 2023-05-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Biocept Reports First Quarter 2023 Financial Results

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three...

Revised Proxy Soliciting Materials (definitive) (defr14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Proxy Statement (definitive) (def 14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Current Report Filing (8-k)

BIOCEPT INC false 0001044378 0001044378 2023-04-17 2023-04-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Biocept Reports 2022 Financial Results

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12...

Amended Quarterly Report (10-q/a)

Q30001044378true--12-310001044378us-gaap:ConvertiblePreferredStockMember2022-01-012022-09-300001044378us-gaap:HealthCarePatientServiceMember2022...

Current Report Filing (8-k)

BIOCEPT INC false 0001044378 0001044378 2023-04-14 2023-04-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Current Report Filing (8-k)

BIOCEPT INC false 0001044378 --12-31 0001044378 2023-04-10 2023-04-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Biocept Inc (BIOC)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

BIOC Actualités

Notice of Effectiveness (effect)

Biocept Announces Pricing of $5.0 Million Underwritten Public Offering

Securities Registration Statement (s-1/a)

Biocept Announces One-for-Thirty Reverse Stock Split

Securities Registration Statement (s-1/a)

Securities Registration Statement (s-1/a)

Current Report Filing (8-k)

Biocept Reports First Quarter 2023 Financial Results

Revised Proxy Soliciting Materials (definitive) (defr14a)

Proxy Statement (definitive) (def 14a)

Current Report Filing (8-k)

Biocept Reports 2022 Financial Results

Amended Quarterly Report (10-q/a)

Current Report Filing (8-k)

Current Report Filing (8-k)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Biocept Inc (BIOC) Actualités

Biocept Inc (BIOC)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

BIOC Actualités

Notice of Effectiveness (effect)

Biocept Announces Pricing of $5.0 Million Underwritten Public Offering

Securities Registration Statement (s-1/a)

Biocept Announces One-for-Thirty Reverse Stock Split

Securities Registration Statement (s-1/a)

Securities Registration Statement (s-1/a)

Current Report Filing (8-k)

Biocept Reports First Quarter 2023 Financial Results

Revised Proxy Soliciting Materials (definitive) (defr14a)

Proxy Statement (definitive) (def 14a)

Current Report Filing (8-k)

Biocept Reports 2022 Financial Results

Amended Quarterly Report (10-q/a)

Current Report Filing (8-k)

Current Report Filing (8-k)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités